Skip to main content
. 2017 Aug 6;8(40):66925–66939. doi: 10.18632/oncotarget.19963

Figure 12. Ov-Mito-Signature 3 predicts patient outcome in ovarian cancer patients.

Figure 12

Note that high levels of Ov-Mito-Signature 3 (NDUFA3/UQCRFS1/PCNA) effectively predicts overall survival (OS), and progression-free survival (PFS).